Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events

Abstract
No abstract available
Funding Information
  • National Institutes of Health (UL1RR024153, UL1TR000005, U54TR001368, P30DK072482)
  • UK National Institute for Health Research
  • Royal Brompton and Harefield National Health Service (NHS) Foundation Trust
  • Imperial College London

This publication has 14 references indexed in Scilit: